Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Says “No Major Impact” from Ranbaxy’s Relinquishment of Marketing Exclusivity
February 1, 2012
- Shuichi Watanabe to Become President, Sadatake Kumakura Chairman: Medipal HD
February 1, 2012
- Apr-Dec Net Profits Down 78% due to Ranbaxy Settlement Fee: Daiichi Sankyo
February 1, 2012
- Kyowa Hakko Kirin Withdraws Application for Additional Indication for Nesp
February 1, 2012
- Kyowa Kirin Development Chief Hanai Set to Become Company President
February 1, 2012
- Apr-Dec Sales Drop 1.2% due to Impact of Great East Japan Earthquake: MTPC
February 1, 2012
- Shared Awareness of Goals Needed in Industry-Academia Collaborations: Dr Teshirogi of Shionogi
February 1, 2012
- Patient Enrollment for All-case PMS for Imusera, Telavic Making Steady Progress: MTPC
February 1, 2012
- Mochida Pharmaceutical Sees Double-Digit Growth in Apr-Dec on Growth of Epadel
January 31, 2012
- DSP to Set Up New Chemical Research Building at Osaka Research Center
January 31, 2012
- Apr-Dec Sales Drop 8.5% due to Slump of US Subsidiary: Shionogi
January 31, 2012
- Shionogi to Set Up Development Site in Europe to Accelerate Global Development
January 31, 2012
- Takeda Initiates Domestic PIII Clinical Trials for New Prostate Cancer Drug, TAK-700
January 30, 2012
- Medisa Shinyaku’s Kyushu Plant Transfers to Sawai
January 30, 2012
- US Sales of Abilify in 2011 Post $3.96 Billion: Otsuka HD
January 30, 2012
- CMIC Chairman Nakamura Keen to “Create Profit-Generating Mechanism” for Ultra-Orphan Drugs
January 27, 2012
- Sawai Refrains from Promotion of Aricept Generics due to Tough Price Competition
January 27, 2012
- Baxter of US to Begin New Global PIII Trial of Immunoglobulin for the Treatment of Alzheimer’s Disease
January 27, 2012
- Novartis Eyes Market Penetration with pNET Indication for Afinitor, Prolonged QOL for Patients
January 26, 2012
- Abbott Sets Up New Unit With MRs Specializing in CNS, Anesthetics for Luvox Transfer
January 26, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…